Phase I trial of alpha-tocopherol effects on 13-cis-retinoic acid toxicity

Annals of Oncology

Volumn 8, Issue 1, 1997, Pages 85-89

  Dimery, I W ^a,b   Hong, W K ^a   Lee, J J ^a   Guillory Perez, C ^a   Pham, F ^a   Fritsche Jr , H A ^a   Lippman, S M ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

phase I trial; retinoid; solid tumors; vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ANTIDOTE; ISOTRETINOIN; RETINOID;

ADULT; AGED; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DRUG TOXICITY; FEMALE; HUMAN; MALE; ORAL DRUG ADMINISTRATION; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL;

EID: 0031055451     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1008209525671     Document Type: Article

References (28)

1. Lippman SM, Kessler JF, Meyskens FL. Retinoids as preventive and therapeutic anticancer agents. Cancer Treat Rep 1987; 71: 493-515.
2. Smith MA, Parkinson DR, Cheson BD et al. Retinoids in cancer therapy. J Clin Oncol 1992; 10: 839-64.
3. Lippman SM, Benner SE, Hong WK et al. Cancer chemoprevention. J Clin Oncol 1994; 12: 851-73.
4. Davies P, Lippman SM. Biologic basis of retinoid pharmacology: Implications for cancer prevention and therapy. Adv Oncol 1996; 12: 2-10.
5. Hong WK, Endicott J, Itri LM et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986; 315: 1501-5.
6. Hong WK, Lippman SM, Itri LM et al. Prevention of second primary tumor with isotretinoin in squamous cell carcinoma of the head and neck. N Engl J Med 1990; 323: 795-801.
7. Kraemer KH, Digiovanna JJ, Moshell AN et al. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N Engl J Med 1988; 318: 1633-7.
8. Lotan R, Xu C, Lippman SM et al. Suppression of retinoic acid receptor β in oral premalignant lesions and its upregulation by isotretinoin. N Engl J Med 1995; 332: 1405-10.
9. Lippman SM, Batsakis JG, Toth BB et al. Comparison of low-dose isotretinoin with beta-carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328: 15-20.
10. Yasutoshi M, Hisatka M, Mitsuo N et al. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. N Engl J Med 1996; 334: 1561-7.
11. Cheng A, Su I, Chen C et al. Use of retinoic acids in the treatment of peripheral T-cell lymphoma: A pilot study. J Clin Oncol 1994; 12: 1185-92.
12. Castleberry RP, Emanuel PD, Zuckaman KS et al. A pilot study of isotretinoin in the treatment of juvenile chronic myelogenous leukemia. N Engl J Med 1994; 331: 1680-4.
13. Lippman SM, Parkinson DR, Itri L et al. 13-cis retinoic acid plus interferon-alpha: Effective therapy for advanced squamous cell carcinoma of the skin. J Natl Cancer Inst 1992; 84: 235-41.
14. Motzer RJ, Schwartz L, Murray-Law T et al. Interferon alfa-2a and 13-cis retinoic acid in renal cell carcinoma: Antitumor activity in a phase II trial and interactions in vitro. J Clin Oncol 1995; 13: 1950-7.
15. Delaney TF, Afridi N, Taghian AG et al. 13-cis-retinoic acid with alpha-2a-interferon enhances radiation cytotoxicity in head and neck squamous cell carcinoma in vitro. Cancer Res 1996; 56: 2277-80.
16. Kolla V, Lindner DJ, Weihua X et al. Modulation of interferon-inducible gene expression by retinoic acid: Upregulation of stat 1 protein in IFN-unresponsive cells. J Biol Chem 1996; 271: 10508-14.
17. Gianni M. Terao M, Fortino I et al. Statl is induced and activated by all-trans retinoic acid in acute promyelocytic leukemia cells. Blood (in press).
18. Besa EC, Abrahms JL, Nowell PC. Increased survival in myelody-plastic syndrome (MDS) patients on high-dose long term 13-cis-retinoic acid (RA). Decrease of RA toxicity with alpha-tocopherol (AT). Proc Am Soc Clin Oncol 1987; 6: 1501.
19. Besa EC, Abrahm JL, Bartholomew MJ et al. Treatment with 13-cis-retinoic acid in transfusion-dependent patients with myelodys-plastic syndrome and decreased toxicity with addition of alpha-tocopherol. Am J Med 1990; 89: 739-47.
20. Davis AW, Moore T. Interaction of vitamin A and E. Nature 1941; 147: 794-6.
21. McCuaig LW, Motzok I. Excessive dietary E: Its alleviation of hypervitaminosis A and lack of toxicity. Poul Sci 1990; 49: 1050-1.
22. Sklan D, Donoghue S. Vitamin E response to high dietary vitamin A in the chick. J Nutr 1982; 112: 759-65.
23. Benner SE, Winn RJ, Lippman SM et al. Regression of oral leukoplakia with alpha-tocopherol: A community clinical oncology program chemoprevention study. J Natl Cancer Inst 1993; 85: 44-7.
24. Ajani JA, Welch SR, Raber MN et al. Comprehensive criteria for assessing therapy-induced toxicity. Cancer Invest 1990; 8: 147-59.
25. Sowell AL, Huff DL, Yeager PR et al. Retinol, α-tocopherol, lutein/zeaxanthin, β-cryptoxanthin, lycopene, α-carotene, trans-β-carotene. and four retinyl esters in serum determined simultaneously by reversed-phase HPLC with multiwavelength detection. Clin Chem 1994; 40: 411-6.
26. Hansen LG, Warwick WJ. A fluorometric micro method for serum tocopherol. Tech Bull Regist Med Technol 1966; 34: 131-6.
27. Woolson RF. Statistical Methods for the Analysis of Biomedical Data. New York: John Wiley & Sons 1997.
28. Goodman GE, Einspahr JG, Alberts DS et al. Pharmacokinetics of 13-cis-retinoic acid in patients with advanced cancer. Cancer Res 1982; 42: 2087-91.